[全反式维甲酸治疗急性早幼粒细胞白血病的疗效：一项多中心研究的初步结果]

[Effectiveness of trans-retinoic acid in the treatment of acute promyelocytic leukemia: initial results of a multicenter study].

作者信息

Parovichnikova E N, Savchenko V G, Kliasova G A, Isaev V G, Demidova I A, Ol'shanskaia Iu V, Tiurina N G, Tikhonova L Iu, Galstian G M, Pivnik A V

出版信息

Ter Arkh. 1999;71(7):20-4.

PMID:10481862

Abstract

AIM

Evaluation of trans-retinoic acid (ATRA) in combination with cytostatic drugs in treatment of acute promyelocytic leukemia (APL).

MATERIALS AND METHODS

In a multicenter study APL was treated according to protocols APL 01.97 and APL 06.87 in 28 patients (14 males and 14 females, median age 36 years).

RESULTS

Administration of ATRA in combination with standard program 7 + 3 (cytosine-arabinoside 100 mg/m2 twice a day v.v. day 1-7, daunorubicin 60 mg/m2 v.v. day 1-3) induced a complete remission in 25 patients (90%). Early lethality was 10% (3 patients died). Resistant APL was not registered. Retinoid syndrome was diagnosed in 15 patients, one patient died. 2-year overall and recurrence-free survival made up 72 and 82%, respectively.

CONCLUSION

ATRA combination with cytosine-arabinoside and daunorubicin is a novel treatment of acute promyelocytic leukemia providing a high rate of complete remission and long-term survival.

摘要

目的

评估全反式维甲酸（ATRA）联合细胞毒性药物治疗急性早幼粒细胞白血病（APL）的效果。

材料与方法

在一项多中心研究中，28例患者（14例男性和14例女性，中位年龄36岁）按照APL 01.97和APL 06.87方案接受治疗。

结果

ATRA联合标准的7 + 3方案（阿糖胞苷100 mg/m²，每日2次，静脉滴注，第1 - 7天；柔红霉素60 mg/m²，静脉滴注，第1 - 3天）治疗，25例患者（90%）实现完全缓解。早期死亡率为10%（3例患者死亡）。未出现耐药的APL病例。15例患者被诊断为维甲酸综合征，1例患者死亡。2年总生存率和无复发生存率分别为72%和82%。